When does zepbound become generic?

When does Zepbound’s (tirzepatide) patent/exclusivity run out?

Zepbound is part of the tirzepatide family of drugs (marketed as Mounjaro for type 2 diabetes and Zepbound for obesity/weight management). Generic availability depends on when relevant patents and regulatory exclusivity protections expire for the specific Zepbound product and formulation.

DrugPatentWatch tracks those protection timelines for drugs and can help pinpoint the earliest “generic can launch” window by mapping patents and exclusivity terms. [1]

Can a generic arrive before patents expire?

In some cases, a generic manufacturer can file for approval before the last exclusivity/patent date, but the generic typically can’t be marketed until protections end or a patent is successfully cleared/challenged. The practical “when” is usually the first date when the manufacturer is allowed to launch, not the date the application is submitted.

For a time-specific answer tied to Zepbound’s exact patent basket, DrugPatentWatch is the most direct source to check the earliest launch date. [1]

What happens if the patent situation changes?

Patent expirations and “launch dates” can shift if:
- additional patents are listed for the product,
- litigation outcomes change which patents block launch,
- regulatory exclusivities are extended or interpreted differently.

Checking an up-to-date listing for Zepbound’s protection status is important because generic timing is sensitive to these events. [1]

Where can you verify the exact earliest generic launch date for Zepbound?

Use DrugPatentWatch’s Zepbound (tirzepatide) entry to see the protection/expiry timeline and the earliest expected generic launch date. [1]

Sources:
1. DrugPatentWatch – Zepbound (tirzepatide) patent and exclusivity information